Department of Anesthesiology, Nationwide Children's Hospital and the Ohio State University, Columbus, OH, USA.
Pediatr Crit Care Med. 2012 Jul;13(4):423-7. doi: 10.1097/PCC.0b013e318238b81c.
Although generally effective for sedation during noninvasive procedures, dexmedetomidine as the sole agent has not been uniformly successful for invasive procedures. To overcome some of the pitfalls with dexmedetomidine as the sole agent, there are an increasing number of reports regarding its combination with ketamine. This article provides a descriptive account of the reports from the literature regarding the use of a combination of dexmedetomidine and ketamine for procedural sedation.
A computerized bibliographic search of the literature regarding dexmedetomidine and ketamine for procedural sedation.
The literature contains four reports with cohorts of more than ten patients with a total of 122 patients. Two of these studies were prospective randomized trials. Additionally, there are eight single case reports or small case series (six patients or less) with an additional 21 pediatric patients. When used together, dexmedetomidine may prevent the tachycardia, hypertension, salivation, and emergence phenomena from ketamine, whereas ketamine may prevent the bradycardia and hypotension, which has been reported with dexmedetomidine. An additional benefit is that the addition of ketamine to initiate the sedation process speeds the onset of sedation, thereby eliminating the slow onset time when dexmedetomidine is the sole agent. Although various regimens have been reported in the literature, the most effective regimen appears to be the use of a bolus dose of both agents, dexmedetomidine (1 µg/kg) and ketamine (1-2 mg/kg), to initiate sedation. This can then be followed by a dexmedetomidine infusion (1-2 µg/kg/hr) with supplemental bolus doses of ketamine (0.5-1 mg/kg) as needed.
The available literature except for one trial is favorable regarding the utility of a combination of ketamine and dexmedetomidine for procedural sedation. Future studies with direct comparisons to other regimens appear warranted for both invasive and noninvasive procedures.
尽管右美托咪定作为单一药物通常可有效用于非侵入性操作的镇静,但在侵入性操作中并非始终有效。为了克服右美托咪定作为单一药物的一些缺陷,越来越多的报道涉及到它与氯胺酮的联合应用。本文提供了一份关于右美托咪定与氯胺酮联合用于程序镇静的文献报告的描述性说明。
对涉及右美托咪定和氯胺酮用于程序镇静的文献进行计算机化文献检索。
文献中包含四项超过十例患者的队列研究,共有 122 例患者。其中两项研究为前瞻性随机试验。此外,还有八例单病例报告或小病例系列(六例或更少),另外还有 21 例儿科患者。当两者联合使用时,右美托咪定可能预防氯胺酮引起的心动过速、高血压、唾液分泌和苏醒现象,而氯胺酮可能预防右美托咪定引起的心动过缓和低血压。另一个好处是,在开始镇静过程中添加氯胺酮可以加速镇静的开始,从而消除了仅使用右美托咪定时缓慢的起始时间。尽管文献中报道了各种方案,但最有效的方案似乎是使用右美托咪定(1μg/kg)和氯胺酮(1-2mg/kg)的联合负荷剂量来开始镇静,然后根据需要给予右美托咪定输注(1-2μg/kg/hr)和补充氯胺酮(0.5-1mg/kg)的负荷剂量。
除一项试验外,现有的文献均对氯胺酮和右美托咪定联合用于程序镇静的有效性持肯定态度。对于侵入性和非侵入性操作,似乎需要进行与其他方案进行直接比较的未来研究。